Headline: Prostate SBRT results in biochemical control at 5 years that is similar to conventional fractionation.
The Study: PACE-B is one of the large randomized trials comparing SBRT and conventional fractionation for prostate cancer. We’ve seen the acute and 2-year toxicity outcomes from prostate SBRT in the PACE-B trials. At ASTRO 2023, we get a peak at the treatment outcomes. As a reminder, 874 men with low (9.3%) or intermediate risk (90.7%) prostate cancer were randomized to SBRT (40 Gy in 5 fractions) or conventional/hypofractionation (78 Gy in 39 fractions or 62 Gy in 20 fractions) without ADT. At 5 years, there was no difference in the rate of freedom from biochemical failure between SBRT and CF/HF (95.7% v 94.6%), and SBRT was deemed non-inferior. Also at 5 years, RTOG grade 2+ GU toxicity was 5.5% after SBRT and 3.2% after CF/HF. Only one patient in each arm had grade 2+ GI toxicity at 5 years.
TBL: In PACE-B, 40 Gy in 5 fractions resulted in 5-year biochemical control that is comparable to 78 Gy in 39 fractions or 62 Gy in 20 fractions. | van As, ASTRO 2023
The Study: PACE-B is one of the large randomized trials comparing SBRT and conventional fractionation for prostate cancer. We’ve seen the acute and 2-year toxicity outcomes from prostate SBRT in the PACE-B trials. At ASTRO 2023, we get a peak at the treatment outcomes. As a reminder, 874 men with low (9.3%) or intermediate risk (90.7%) prostate cancer were randomized to SBRT (40 Gy in 5 fractions) or conventional/hypofractionation (78 Gy in 39 fractions or 62 Gy in 20 fractions) without ADT. At 5 years, there was no difference in the rate of freedom from biochemical failure between SBRT and CF/HF (95.7% v 94.6%), and SBRT was deemed non-inferior. Also at 5 years, RTOG grade 2+ GU toxicity was 5.5% after SBRT and 3.2% after CF/HF. Only one patient in each arm had grade 2+ GI toxicity at 5 years.
TBL: In PACE-B, 40 Gy in 5 fractions resulted in 5-year biochemical control that is comparable to 78 Gy in 39 fractions or 62 Gy in 20 fractions. | van As, ASTRO 2023